Related Experiment Videos
[Non-invasive prenatal diagnosis--already a reality?]
Wolfang Holzgreve1, Sinuhe Hahn
1Universitäts-Frauenklinik Basel, Schweiz, Germany. wholzgreve@uhbs.ch
Gynakologisch-Geburtshilfliche Rundschau
|June 22, 2002
Summary
Analyzing fetal DNA in maternal blood offers a non-invasive prenatal diagnosis. Cell-free fetal DNA in plasma is highly reliable for genetic traits, moving prenatal testing from lab to clinic.
Area of Science:
- Genetics
- Molecular Biology
- Obstetrics
Context:
- Non-invasive prenatal diagnosis (NIPD) aims to analyze fetal genetic material from maternal samples.
- Previous methods focused on enriching fetal cells from maternal blood, facing technological limitations for routine use.
- Large-scale studies like the NIH 'NIFTY Study' highlighted the potential but also the current technological gaps.
Purpose:
- To evaluate the feasibility and reliability of using cell-free fetal DNA (cfDNA) in maternal plasma for prenatal genetic analysis.
- To compare the efficacy of cfDNA analysis with traditional fetal cell enrichment methods.
- To identify specific fetal genetic traits that can be reliably detected using cfDNA.
Summary:
- The analysis of cell-free fetal DNA (cfDNA) circulating in maternal plasma has emerged as a highly reliable method for prenatal genetic testing.
- This cfDNA approach has demonstrated exceptional accuracy in identifying fetal genetic traits, such as fetal RhD status.
- Unlike earlier methods relying on fetal cell isolation, cfDNA analysis has successfully transitioned from research settings to clinical application.
Impact:
- Enables non-invasive prenatal diagnosis, reducing risks associated with invasive procedures.
- Provides a reliable method for determining fetal RhD status, crucial for managing hemolytic disease of the newborn.
- Represents a significant advancement in prenatal screening, paving the way for broader clinical adoption of molecular diagnostics.